Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date

doi:10.4239/wjd.v10.i10.490

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (16581)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

1460

WORD

305

HTML

12340

Figures (1-6)

747

Tables (1-3)

230

Sum=15082

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

720

Download

779

Sum=1499

Oct 15, 2019 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (61)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Oct 15, 2019; 10(10): 490-510
Published online Oct 15, 2019. doi: 10.4239/wjd.v10.i10.490

Full Size Figure Download Figure

Figure 6 Major cardiovascular outcome trials examining SGLT2 inhibitors.

Citation: Athithan L, Gulsin GS, McCann GP, Levelt E. Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date. World J Diabetes 2019; 10(10): 490-510
URL: https://www.wjgnet.com/1948-9358/full/v10/i10/490.htm
DOI: https://dx.doi.org/10.4239/wjd.v10.i10.490